L Robinson

Molecular-level effects of radiation on Li/CFx batteries, components, and interphases: radiation-induced defects in LiF

L Robinson, John‐Paul Jones, Sarah Stariha, Hui Li Seong et autres

us (code pays fourni par la source)

Dupilumab Efficacy and Safety in Patients with Moderate-to-Severe COPD with Type 2 Inflammation: Pooled Analysis of BOREAS and NOTUS Trials

Shweta Bhatt, A Hoheisel, Klaus F. Rabe, NA Hanania et autres

Introduction: BOREAS (NCT03930732) and NOTUS (NCT04456673), 52-week, phase 3, randomized, double-blind, placebo-controlled trials demonstrating dupilumab efficacy and safety data in patients with COPD. Objective: To evaluate the safety and efficacy of dupilumab in a pooled analysis combining both BOREAS and NOTUS. Methods: …

us, de, gb, it (code pays fourni par la source)

Dupilumab Improves Health-Related Quality of Life in Patients with Chronic Obstructive Pulmonary Disease and Type 2 Inflammation: Pooled Boreas and Notus Results

Shweta Bhatt, Benjamin Waschki, Klaus F. Rabe, NA Hanania et autres

Purpose: Impaired quality of life contributes significantly to morbidity in chronic obstructive pulmonary disease (COPD). St. George’s Respiratory Questionnaire (SGRQ) is a patient-reported outcome measure of health-related quality of life (HRQoL) in respiratory disease. Methods: BOREAS (NCT03930732) and NOTUS (NCT04456673) were phase …

us, de, gb, it (code pays fourni par la source)

Dupilumab Reduces Exacerbations and Improves Lung Function and Quality of Life in Patients with Chronic Obstructive Pulmonary Disease and Type 2 Inflammation: The Notus Trial

Shweta Bhatt, A Hoheisel, Klaus F. Rabe, NA Hanania et autres

Introduction: Phase 3 BOREAS (NCT03930732) demonstrated efficacy and a significant reduction in exacerbation frequency in patients (pts) with chronic obstructive pulmonary disease (COPD) and type 2 inflammation. Phase 3 NOTUS (NCT04456673) aimed to confirm the efficacy and safety of dupilumab (DPL) in …

us, de, gb, it (code pays fourni par la source)

Development of Fluoride-Ion Primary Batteries

L Robinson, Jonah Wang, Harrison Asare, Jessica L. Andrews et autres

The primary lithium-carbon monofluoride (Li-CFx) cell offers the highest specific energy of any commercial lithium metal battery chemistry known. However, the practical discharge voltage even at low current densities (ca. 2.5-2.7 V) is significantly lower relative to the theoretical value (4.57 V), …

Development of Fluoride-Ion Primary Batteries: The Electrochemical Defluorination of CFx

L Robinson, Jonah Wang, Harrison Asare, Jessica L. Andrews et autres

High Resolution Image Download MS PowerPoint Slide The lithium–carbon monofluoride (Li-CF x ) couple has the highest specific energy of any practical battery chemistry. However, the large polarization associated with the CF x electrode (>1.5 V loss) limits it from achieving its …

us, pr (code pays fourni par la source)

Elucidating the Role of Electrochemically Formed LiF in Discharge and Aging of Li-CFx Batteries

Theresa Schoetz, L Robinson, Leo W. Gordon, Sarah A. Stariha et autres

Fifty years after its introduction, the lithium-carbon monofluoride (Li-CF x ) battery still has the highest cell-level specific energy demonstrated in a practical cell format. However, few studies have analyzed how the main electrochemical discharge product, LiF, evolves during the discharge and …

us (code pays fourni par la source)

Efficacy and Safety of Dupilumab for COPD with Type 2 Inflammation Indicated by Elevated Eosinophils

Shweta Bhatt, Henrik Watz, Klaus F. Rabe, NA Hanania et autres

Introduction: Dupilumab (DPL), a fully human mAb, blocks the shared receptor component for IL-4 and IL-13, key/central drivers of Type 2 (T2) inflammation. The objective is to determine efficacy/safety in patients with moderate-to-severe COPD with T2 inflammation. Methods: BOREAS (NCT03930732) was a …

us, de, gb, it (code pays fourni par la source)

Assessment of the long-term safety and efficacy of dupilumab in children with asthma: LIBERTY ASTHMA EXCURSION

Eckard Hamelmann, Leonard B. Bacharier, J Maspero, Constance H. Katelaris et autres

Introduction Dupilumab (DPL), a fully human mAb, blocks the shared receptor component for IL 4/13. The efficacy and safety of add-on DPL versus placebo (PBO) in children with asthma have been demonstrated up to 52 weeks (wks) in the VOYAGE study. Aim …

de, us, au, it, fr (code pays fourni par la source)

Assessment of the long-term safety and efficacy of dupilumab in children with asthma: LIBERTY ASTHMA EXCURSION

L Bacharier, J F Maspero, C. H. Katelaris, A Fiocchi et autres

Introduction: Dupilumab (DPL), a fully human mAb, blocks the shared receptor component for IL‑4/13. The efficacy and safety of DPL in children with asthma have been demonstrated up to 52 weeks (wks) in the VOYAGE study. Aim: This open-label extension (OLE) study …

us, ar, au, it, fr (code pays fourni par la source)